Loading…

Loading grant details…

Active NON-SBIR/STTR RPGS NIH (US)

Mechanisms of DNA methylation signaling and dysregulation in colon cancer

$6.32M USD

Funder NATIONAL CANCER INSTITUTE
Recipient Organization Van Andel Research Institute
Country United States
Start Date Jul 02, 2024
End Date Jun 30, 2029
Duration 1,824 days
Number of Grantees 1
Roles Principal Investigator
Data Source NIH (US)
Grant ID 10979595
Grant Description

PROJECT SUMMARY Colon cancer is a leading cause of cancer-related death for both men and women in the United States. Abnormal DNA methylation patterning is an epigenetic hallmark of colon and other cancer types and is a major contributing factor to genome instability and tumor suppressor gene silencing in this disease. Despite a deep appreciation of

roles for DNA methylation in development and cancer, causal mechanisms that contribute to the evolution of DNA methylation abnormalities in colon and other cancer types, and consequences of this hallmark epigenetic remodeling on cancer development, remain poorly understood. This proposal seeks to address these

fundamental knowledge gaps. Our preliminary data implicate protein ubiquitination as an essential post- translational modification (PTM) regulating the activity of DNMT1, the primary enzyme responsible for the epigenetic inheritance of DNA methylation patterns through mitotic cell divisions and a major target for epigenetic

cancer therapy. Building from these data, studies in Aim 1 will characterize the ubiquitin signaling network that interfaces with DNA methylation inheritance. The therapeutic potential of targeting ubiquitin signaling regulators in this pathway will also be considered. In Aim 2, we will test a mechanistic hypothesis connecting overexpression

of the E3 ubiquitin ligase UHRF1 to DNA methylation dysregulation and colon tumorigenesis. Aim 3 will investigate a non-canonical function for UHRF1 in the regulation of heterochromatic histone PTM signaling and its implications for DNA hypomethylation therapy. Overall, our studies at the interface of ubiquitin signaling and

DNA methylation inheritance will reveal fundamental causes and consequences of abnormal DNA methylation signaling in colon cancer and identify novel approaches to enhance the efficacy of DNA hypomethylation therapy as a treatment strategy to manage this deadly disease.

All Grantees

Van Andel Research Institute

Advertisement
Discover thousands of grant opportunities
Advertisement
Browse Grants on GrantFunds
Interested in applying for this grant?

Complete our application form to express your interest and we'll guide you through the process.

Apply for This Grant